Teva Pharmaceutical Ltd $TEVA said on Thursday that its late-stage study on candidate SD-809 intended for treating tardive dyskinesia showed good results. The drug-maker will file for the regulatory application, New Drug Application (NDA), later this year. The Top-line results from Phase 3 clinical trial, AIM-TD, showed clinical efficacy of the drug. SD-809 is an orally available small molecule inhibitor of vesicular monoamine 2 transporter (VMAT2) that is intended to control the levels of the neurotransporter dopamine in the brain.